Diabetic Retinopathy in China 2026: cost by stage

There is no single price for diabetic retinopathy, because it isn't a single procedure — it's a spectrum that runs from a $120 monitoring visit to $3,000–5,000 vitrectomy surgery, and the stage you're at decides both the treatment and whether flying anywhere is sensible at all. This guide prices each stage in China as researched in July 2026, then answers the question the cost pages skip: diabetic eye disease is chronic and schedule-driven, so which stages actually suit medical travel — and which ones you should treat at home.

Stage first: where you are decides everything

Diabetic retinopathy is staged on what the retina shows, and separately on whether the macula — the small central area you read with — is swollen. Those two axes, not the price list, determine your options:

If nobody has actually staged your eyes with a dilated examination and an OCT scan, that's the first thing to buy — anywhere. A quote for treatment written before staging is not a medical plan.

What each stage costs (researched July 2026)

Ranges are standard partner-hospital fee schedules researched July 2026, against published US private-pay references; Western-European private rates typically sit 20–35% below the US figures. Diabetic vitrectomy sits above the general vitrectomy range on our glaucoma & retina cost guide ($2,500–4,500) for a real clinical reason: diabetic cases often involve dissecting fibrovascular membranes off a fragile retina, endolaser during surgery, and sometimes a tamponade — longer operating time and more consumables than a straightforward macular-hole or membrane case. Anyone quoting diabetic vitrectomy at the bottom of a generic vitrectomy range hasn't seen your imaging. For every other procedure, see the full China eye surgery price guide.

Diabetic macular edema is not a stage — it is a second disease on the same retina

The staging table above tells you how much abnormal vessel growth your retina has. It does not tell you whether the centre of your macula is waterlogged, and those two things travel separately. You can have mild non-proliferative retinopathy and sight-threatening macular edema. You can have full proliferative disease and a dry macula. Diabetic macular edema (DME) runs on its own axis, it is the commonest reason people with diabetes lose reading vision, and almost every treatment decision, price estimate and travel plan on this page changes depending on which of those two things you actually have.

This matters commercially as well as clinically, because it is the thing most often blurred in a quote. "Diabetic retinopathy treatment, from $300" is an injection price, and an injection is a DME treatment. If your problem is proliferative disease with a dry macula, the injection price is not your price — laser and surgery are. If your problem is DME, the laser price is largely not your price either. Work out which disease you are being quoted for before you compare a single number.

Centre-involving or not: the distinction that decides whether you are treated at all

Retina specialists split DME by where the thickening sits relative to the exact centre of the macula. Centre-involving DME (CI-DME) is thickening at the foveal centre — the part of the retina you read with. Non-centre-involving DME is thickening nearby but sparing the centre. The distinction is not cosmetic: non-centre-involving edema with good vision is commonly monitored or treated with focal/grid macular laser, the $200–450 line on the table above, while the injection conversation belongs mostly to centre-involving disease. Two people with the same "diabetic macular edema" on a referral letter can therefore be looking at wildly different years.

What decides it is a measurement, not an opinion: central subfield thickness on OCT, the average retinal thickness in the 1 mm circle centred on the fovea. Three practical points that almost no destination page will tell you:

• The number is machine-specific. Different OCT platforms segment the retina slightly differently and produce systematically different thickness values for the same eye, which is why the normal thresholds published for one machine do not transfer to another. A thickness measured in China is only comparable with your home baseline if the machine and scan protocol are comparable — or if someone re-measures both. Ask which platform was used and get it written on the report.
• Bring two scans from different dates, not one. A single OCT shows a state. Two show a direction, and direction is what a treatment decision turns on. This is the same rule we apply to keratoconus and to thyroid eye disease, and it is worth arranging the second scan at home before you book anything.
• Bring the images, not the report. A PDF summary with a thickness number cannot be re-read. The raw scans can.

The finding no facilitator page will show you: good vision may mean no injection at all

If you have been told you have centre-involving DME but you can still read the 20/25 line, there is a large, well-conducted trial that speaks directly to you, and its result is inconvenient for anyone selling treatment. The DRCR Retina Network's Protocol V randomised 702 eyes with centre-involving DME and visual acuity of 20/25 or better to three strategies: immediate aflibercept injections, focal/grid laser, or observation — with aflibercept given in the laser and observation groups only if vision subsequently dropped.

Read the last row twice. Over two years, roughly two thirds of the observation eyes never needed an injection, and the eyes that were watched ended up in much the same place as the eyes that were injected from day one. For this specific group — centre-involving edema, good acuity — careful monitoring with regular OCT is an evidence-based plan, not neglect. It is also not a plan that requires a flight. If that is you, the most useful thing this page can do is tell you to keep your monitoring appointments at home and spend nothing.

If vision is already reduced, which drug is used starts to matter

The companion trial, Protocol T, compared aflibercept, bevacizumab and ranibizumab head to head in centre-involving DME. At two years mean acuity gains were 12.8, 10.0 and 12.3 letters respectively — but the average conceals the finding that is actually useful, which is that the answer depends on where you started:

Two honest limits on how far you can push that. First, Protocol T tested three specific molecules; it did not test conbercept or China's domestic biosimilars head-to-head in that severity band, so it is evidence about a class of decision, not a ranking of the Chinese menu described below. Second, a trial average is not a prediction about your eye — a meaningful minority of DME eyes respond incompletely to any agent, which is why a specialist judges response on repeat OCT rather than on the first injection.

One recent addition worth knowing about but not budgeting on: on 31 July 2026 China's NMPA approved a ready-to-use prefilled-syringe presentation of faricimab (Vabysmo), a bispecific antibody blocking both VEGF-A and Ang-2, for wet AMD, diabetic macular edema and macular edema after retinal vein occlusion. It is a real option in the Chinese market and it is not on the price table above, because no self-pay range for it is established yet. The site's standing rule applies with extra force to anything approved this month: a licence is not a stock. Ask whether the hospital actually holds it and at what price, in writing, before it forms any part of a plan.

The steroid route is the one that genuinely suits a traveller — and the price is paid in the lens

The scheduling problem described above has one real exception. A biodegradable dexamethasone intravitreal implant releases steroid over months rather than weeks: peak effect around three months, with retreatment typically considered somewhere in the four-to-six month window, against roughly four to eight weeks for anti-VEGF maintenance. That is the only DME treatment whose natural interval is compatible with living on another continent, which is why it appears on the "suits travel" side of the box above.

It is not free of consequences, and the trial numbers are specific enough to plan around. In the MEAD programme, among eyes that still had their natural lens, cataract developed in about 68% of implanted eyes against 21% of sham eyes, and about 61% went on to cataract surgery against 8%. Intraocular pressure rose by 10 mmHg or more at some visit in 28% of implanted eyes against 4%, generally peaking around six weeks and settling by six months, and generally manageable with drops.

Which is why the implant is most often discussed for eyes that already have an artificial lens, or that have responded poorly to anti-VEGF, or where the monthly cadence genuinely cannot be delivered. Read together, that produces the single best-fitting profile on this page for a planned trip: a pseudophakic eye with centre-involving DME and a documented poor or partial response to injections. If you still have your own lens, you are trading a cataract you will probably need operated — sometimes an acceptable trade, sometimes not, and always a decision for the treating retina specialist based on your lens status, your pressure history and how your macula has behaved so far. Note that if the cataract does arrive, it is operable in the same eye and priced separately; that is a cost, not a catastrophe.

What a trip can and cannot buy, for DME specifically

And one arithmetic warning about the price table. The $1,500–3,500 loading-course figure prices five injections; it does not price five flights. Any comparison you make between a Chinese course and a home course has to put the travel on the Chinese side and then count the injections given after you land back home at home prices — which is the first-year framing the next section sets out. Almost every quote in this niche, ours included, is a per-injection number attached to a condition treated on a cadence.

Vitrectomy for DME is a narrower indication than it sounds

Surgery has a defined place in macular edema, and it is smaller than facilitator pages imply. It is considered mainly where the edema has a mechanical component — a taut, thickened posterior hyaloid or an epiretinal membrane dragging on the macula — or where edema has persisted despite an adequate course of injections. In an eye with straightforward leakage and no traction, vitrectomy is not a substitute for medical treatment, and the honest version of the conversation is that surgery is being offered because something is pulling, not because injections are inconvenient. If a quote proposes vitrectomy for DME without OCT evidence of traction or a documented history of failed injections, ask what is being operated on.

Why injections cost less here — and the one case where they don't

Injections are the odd item on the price table above, and it is worth understanding why before you build a plan around them. Laser and vitrectomy are cheaper in China for the ordinary reason: you are buying theatre time, equipment amortisation and a surgeon's hours, and those cost less. An anti-VEGF injection is almost entirely a vial. The procedure wrapped around it — anaesthetic drops, an eyelid speculum, an antiseptic prep, a few minutes in a clean room — is close to identical in Shanghai and in Ohio. So the injection price gap is not a labour story at all. It is a question of which molecule is in the syringe, and what that molecule costs in that country. Which means it can run either way.

The agents actually in use in China

A licence is not a stock. Every agent above is legally available in China; that is a different question from whether the department treating you has it in the fridge this month, at what price, and with what experience behind the choice. Ask about the specific product, not the class. And note what the last two rows mean in aggregate: China's domestic anti-VEGF tier is still widening, which is why any price you read that is more than a year old should be re-confirmed rather than trusted.

The number that matters is the year, not the injection

Almost every quote you will be shown — ours included, above — is a per-injection price. For a condition treated on a cadence, that is half a quote. The other half is how many injections, which depends on the agent, on how your macula responds and on your specialist's judgement. A first year of centre-involving diabetic macular edema in one eye commonly runs to something in the order of five loading injections and then several more at extending intervals. At China's $300–800 per injection, a nine-injection first year is $2,700–7,200 — a spread wider than most people's mental model of "an injection costs a few hundred dollars".

Then comes the part that decides whether travel helps at all: the injections you do not receive in China are priced at home. If a trip supplies the first three of a nine-injection year and your home system supplies the other six, you have saved on a third of the treatment and paid domestic rates for the rest. That is still a real saving if the home rate is US private-pay at $1,800–2,400 an injection. It is not a saving at all in the case immediately below. Work the year, not the vial.

Why China's published drug prices are not the price you will pay

You may come across Chinese figures quoted in renminbi that look lower than anything here. Published cost-effectiveness work using China's 2020 national reimbursement list put the negotiated prices at approximately CNY 4,160 per vial for conbercept and CNY 3,950 for ranibizumab, and the benchmarks have been renegotiated since. Two things follow, and both cut against the naive reading. First, those are the prices at which the national scheme settles for its own enrollees, under conditions attached to indication and treatment course; an overseas visitor is not an enrollee and pays the hospital's self-pay price, which is what the ranges on this page reflect. Second, a reimbursement benchmark is a budget instrument rather than a clinical one — it tells you what a health system will fund, not what your eye needs. Quote it at your own hospital and you will be politely corrected.

Four questions to ask, in writing

• Which drug, specifically? Name and manufacturer, not "anti-VEGF".
• Is it stocked, this month? A licence is not a stock, and substitutions made on the day are how people end up on an agent nobody discussed with them.
• What interval is planned, and how many injections in year one? Then multiply. Interval and unit price both move the annual figure, and a quote that answers only the second is half a quote.
• Who gives injections four through nine, at what price, and have they agreed? If a domestic Chinese agent is used for loading and your home specialist can only continue with a different one, that switch should be a planned, documented decision — not something your next doctor discovers from a discharge summary.

Drug choice is a clinical decision that belongs to the treating retina specialist, weighing your macular anatomy, previous response and how often you can realistically attend. Cheapest vial is not a treatment plan.

Diabetes co-management: the part that isn't ophthalmology

Diabetic eye surgery is safer when the rest of the diabetes is accounted for, and the good Chinese academic centres are set up for this — their ophthalmology departments sit inside large general hospitals with endocrinology and nephrology on the same campus. Practical implications for a trip:

• Bring recent numbers — HbA1c, blood pressure readings, kidney function (eGFR, creatinine, urine protein) and your full medication list including insulin doses, oral agents and any GLP-1 agonist.
• Plan the operating day — fasting for anaesthesia interacts with insulin and oral hypoglycaemics. Ask specifically how your regimen is adjusted, who supervises glucose on the day, and what happens if you run high or low.
• Renal function matters — fluorescein angiography and any general anaesthetic are planned differently in diabetic kidney disease. Don't leave this to be discovered at admission.
• Vision affects insulin safety — if central vision is poor, dose-drawing and glucose monitoring get harder. Worth naming as a goal of treatment rather than an afterthought.
• One genuine subtlety — very rapid tightening of long-standing poor glucose control can transiently worsen retinopathy. This is a known phenomenon that argues for eye monitoring alongside improving control, coordinated between your ophthalmologist and diabetes doctor. It is not an argument against control.

Our for-foreigners guide covers how international departments handle multi-department coordination, English records and payment, and the hospitals guide explains which institutions have the vitreoretinal depth and the general-hospital backing that diabetic cases want. In city terms, Shanghai offers the most retina redundancy across institutions, Beijing is strongest where systemic disease needs to sit beside the eye work, and Guangzhou concentrates subspecialty depth on one campus; the city comparison weighs those trade-offs against flights.

What a trip looks like, by pathway

Vitrectomy patients sometimes receive an intraocular gas bubble, and flying is prohibited until that gas has fully absorbed — weeks, not days, and an absolute rule rather than a preference. Our flying-after-eye-surgery guide explains the physics and the per-procedure windows, including the silicone-oil exception. Build the return ticket around that, and expect the surgeon's clearance to be the deciding voice.

The handover: what you take home

For a chronic disease this is the deliverable that decides whether the trip helped or just interrupted your care. Insist on all of it, in English, before you leave:

• Staging diagnosis for each eye in standard terminology, with macular status stated separately.
• Baseline and post-treatment OCT scans as images, not merely a summary — your home specialist needs to compare, and central retinal thickness numbers alone aren't enough.
• Fundus photographs and any angiography, plus the laser record: parameters and number of PRP spots per eye, so a future clinician knows how much retina has already been treated.
• Injection log — exact drug name, dose, eye and date for each injection given.
• Operative note for any surgery, including tamponade used and positioning instructions.
• The next due date — when the next injection or review should happen. This is the item most often missing, and the one that matters most.

If your case turns out to be glaucoma or another retinal condition rather than diabetic disease, our glaucoma & retina cost guide covers those pathways, and our safety assessment addresses the standards question directly. If the diagnosis instead points to an inherited retinal dystrophy — which can look similar on a first fundus photograph but has a completely different treatment map — our inherited retinal disease guide sets out which routes are actually purchasable in China and which are trials you cannot fly in for.

Frequently asked questions